Cassava Sciences (SAVA.US) receives DSMB approval for its late-stage Alzheimer's disease therapy trial

Market VisionTuesday, Sep 24, 2024 9:30 am ET

1min read

Cassava Sciences(SAVA.US) announced that it has completed its third interim safety review of simufilam in its ongoing Phase 3 clinical trial for Alzheimer's disease patients.

It is understood that the pre-review meeting of the Data and Safety Monitoring Board (DSMB) recommended that the ongoing Phase 3 clinical study of Cassava Sciences should continue as planned without any modifications.

Today's latest news update follows the mid-stage safety MRI data announced in October 2023, which showed that simufilam from Cassava Sciences was not associated with imaging abnormalities related to amyloidosis in the treatment.

Cassava Sciences is a biotechnology company headquartered in Texas, USA, focused on developing innovative drugs to treat Alzheimer's disease. Its main research projects include simufilam, a drug designed to improve cognitive function in Alzheimer's disease patients by restoring the normal structure and function of brain proteins.

Cassava Sciences has garnered significant attention in the clinical trials of Alzheimer's disease treatment drugs. The company's recent major developments regarding simufilam's progress in the Phase 3 clinical trial have attracted high attention from investment institutions focused on biotechnology companies and the medical community. The success of these trials would bring potential breakthrough progress in the treatment of Alzheimer's disease.

The company's stock price rose more than 2% in pre-market trading on the news.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.